RESEARCH TRIANGLE PARK, N.C., May 23, 2024 G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib.
MALVERN, Pa., May 20, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun.
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 ... pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
BioInvent International: BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.